The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MRK | -12.86% | +40.43% | +7.02% | +40,987% |
| S&P | +19.89% | +109.18% | +15.89% | +7,017% |
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.
Learn about some of the leading cancer stocks in the U.S. stock market this year.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $17.28B | 3.4% |
| Gross Profit | $14.15B | 15.3% |
| Gross Margin | 81.92% | 8.5% |
| Market Cap | $209.64B | -27.2% |
| Market Cap / Employee | $2.80M | 0.0% |
| Employees | 75K | 4.2% |
| Net Income | $5.79B | 83.1% |
| EBITDA | $7.42B | 1.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $8.05B | -29.0% |
| Accounts Receivable | $11.85B | 1.8% |
| Inventory | 6.6K | 2.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $33.97B | -2.2% |
| Short Term Debt | $1.43B | -53.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 14.26% | 1.6% |
| Return On Invested Capital | 13.39% | 0.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $2.53B | -47.8% |
| Operating Free Cash Flow | $3.29B | -41.6% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 14.77 | 13.07 | 12.20 | 11.10 | -53.32% |
| Price to Book | 5.66 | 4.90 | 4.12 | 4.29 | -35.10% |
| Price to Sales | 3.95 | 3.56 | 3.14 | 3.28 | -28.59% |
| Price to Tangible Book Value | 43.47 | 27.42 | 18.28 | 17.21 | -67.51% |
| Price to Free Cash Flow TTM | 40.65 | 24.61 | 24.97 | 29.73 | -48.04% |
| Enterprise Value to EBITDA | 57.26 | 45.47 | 32.37 | 30.44 | -34.61% |
| Free Cash Flow Yield | 2.5% | 4.1% | 4.0% | 3.4% | 92.47% |
| Return on Equity | 28.3% | 40.8% | 39.3% | 35.4% | 6.15% |
| Total Debt | $38.13B | $38.27B | $34.84B | $35.40B | -6.31% |
From a big-time patent settlement between Merck & Co. and Bristol-Myers Squibb, to Johnson & Johnson's earnings, to Aetna and Humana's $37 billion merger bust, we dive into the details behind last week's biggest healthcare stories.
Merck, Gilead Sciences, and Ionis get a verdict in their patent suit, and Congress calls for a patent review of Medivation's Xtandi.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
